On April 4, 2022, Optimind Pharma Corp. closed the transaction. The company raised CAD 507,000 in the transaction.

The subscription receipts were exchanged for convertible debentures of the company, with each convertible debenture convertible into a convertible debenture unit of the company at a price of CAD 0.20 per convertible debenture unit, with each convertible debenture unit comprised of a common share and 0.6 of a warrant, with each full warrant exercisable into a common share at an exercise price of CAD 0.30 per share.